Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6176560

N.c1ccc(Cc2ccccn2)nc1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.57
HRH1 P35367 2/20 0.56
HRH3 Q9Y5N1 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.54
MAPT P10636 1/20 0.54
LIN28A Q9H9Z2 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
LMNA P02545 1/20 0.54
TAAR1 Q96RJ0 1/20 0.54
ALDH1A1 P00352 1/20 0.54
ALOX15 P16050 1/20 0.54
HRH4 Q9H3N8 1/20 0.53
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
ASIC3 Q9UHC3 1/20 0.50
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29830938 0.97 L3MBTL1 (0.59) L3MBTL1HRH1HRH3SMN1; SMN2MAPT
SCHEMBL41191 0.97 L3MBTL1 (0.59) L3MBTL1HRH1HRH3SMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL10884973 0.94 L3MBTL1 (0.57) L3MBTL1HRH1HRH3SMN1; SMN2MAPT
SCHEMBL4938207 0.94 L3MBTL1 (0.57) L3MBTL1HRH1HRH3SMN1; SMN2MAPT
SCHEMBL4938201 0.94 L3MBTL1 (0.57) L3MBTL1HRH1HRH3SMN1; SMN2MAPT
Bromide SCHEMBL6114859 0.94 L3MBTL1 (0.57) L3MBTL1HRH1HRH3SMN1; SMN2MAPT
SCHEMBL29715188 0.94 L3MBTL1 (0.57) L3MBTL1HRH1HRH3SMN1; SMN2MAPT
SCHEMBL7948124 0.87 HRH3 (0.55) L3MBTL1HRH1HRH3SMN1; SMN2MAPT
SCHEMBL7948123 0.87 HRH3 (0.55) L3MBTL1HRH1HRH3SMN1; SMN2MAPT
Dipyridyl SCHEMBL4975687 0.87 KDM4E (0.67) L3MBTL1HRH1HRH3SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343497-A4 $g(D)?2 ,-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE K AND K BIOSCIENCES INC (US) 2005-01-26 EP claimed
EP-1343497-A1 $g(D)?2 ,-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE K and K Biosciences, Inc. (US) 2003-09-17 EP claimed
US-20020111371-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCES, INC. 2002-08-15 US claimed
WO-2002036119-A1 Δ2,-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE K AND K BIOSCIENCES, INC. (US) 2002-05-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111371-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C L3MBTL1 1507/4885HRH1 149/4885HRH3 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.